Investing.com - Biomarin Pharma reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Biomarin Pharma announced earnings per share of $0.15 on revenue of $533.8M. Analysts polled by Investing.com EPS of $0.0257 on revenue of $520.35M.
Biomarin Pharma 's are up 0.06% and is trading at $88.21 , still down 6.16% from its 52 week high of $94.20 set on Thursday, February 10, 2022.
Biomarin Pharma shares lost 0.21% to trade at $88.21 in after-hours trade the report.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma's report follows an earnings beat by UnitedHealth on Friday, July 15, 2022, who reported EPS of $5.57 on revenue of $80.33B, EPS of $5.21 on revenue of $79.68B.
J&J had beat expectations on Tuesday, July 19, 2022 with second quarter EPS of $2.59 on revenue of $24.02B, for EPS of $2.54 on revenue of $23.77B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar